Humira boosts Abbott’s results
Abbott Laboratories’ second-quarter profit rose 34% as its top-selling product, anti-inflammatory medicine Humira, was approved for new uses.
Net income jumped to $1.32 billion, or 85 cents a share, from $988.7 million, or 63 cents, a year earlier, the Abbott Park, Ill., company said.
Earnings adjusted for items that include the end of a joint venture beat analysts’ estimates, and Abbott raised its 2008 profit forecast.
Revenue increased 15% to $7.31 billion, also beating analysts’ estimates.
Abbott shares fell 88 cents, or 1.5%, to $56.97.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
